Skip to content

Inspection Record

SciVac LTD — FDA 483 Findings

US FDAInspected 2023-03-27Published 2026-10-26 4 findingsAseptic processing and sterility assuranceDeviation, CAPA, and investigationTraining and personnelQuality unit oversight

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

2Deviation, CAPA, and investigation

Deviations from written production and process control procedures are not recorded or justified.

3Training and personnel

Employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions.

4Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

SciVac LTD company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.